Myriad Genetics Announces Patent Granted for SneakPeek® Snap Device
20 mars 2024 16h05 HE
|
Myriad Genetics, Inc.
SALT LAKE CITY, March 20, 2024 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced that the U.S. Patent and Trademark...
Patent Allowance Granted for P-1 Molecule by US Patent and Trademark Office
20 mars 2024 10h20 HE
|
PharmAla Biotech
PharmAla Recieves Notice of Allowance of Patent on Novel MDMA-like Molecule with improved safety, therapeutic range
Ludwig Enterprises Inc (OTC:LUDG) Enters Booming Artificial Intelligence Cancer Screening Market with its Non-Invasive Cancer Diagnostics Testing Kit, launching within 2024
19 mars 2024 08h00 HE
|
Ludwig Enterprises, Inc.
SPARKS, Nev., March 19, 2024 (GLOBE NEWSWIRE) -- Ludwig Enterprises, Inc, (OTC: LUDG): A US-based biotechnology company is pleased to announce it has entered the booming artificial intelligence...
SciSparc Granted Another Patent, Strengthening its Core Technology in Canada
18 mars 2024 07h29 HE
|
SciSparc Ltd
TEL AVIV, Israel, March 18, 2024 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC) (“Company” or “SciSparc”), a specialty clinical-stage pharmaceutical company focusing on the development of...
NAPIGEN, Inc. Secures U.S. Patent, Awarded USDA SBIR Grant
11 mars 2024 08h15 HE
|
Napigen, Inc.
The USPTO issued a patent to NAPIGEN for the use of CRISPR technologies to edit organellar genomes. Separately, USDA awarded NAPIGEN an SBIR phase 1 grant.
SciSparc Granted Patent for Core Technology in Multiple Jurisdictions in Europe
07 mars 2024 07h49 HE
|
SciSparc Ltd
The Company's most recent patent further solidifies its position, complementing existing grants in the U.S., Japan, Australia and other key jurisdictions TEL AVIV, Israel, March 07, 2024 ...
Ludwig Enterprises Inc. (OTC:LUDG) Announces Patent Filing for Breakthrough in Identifying mRNA Genes Associated with Certain Cancers
06 mars 2024 08h00 HE
|
Ludwig Enterprises, Inc.
Ludwig Enterprises, Inc. (OTC: LUDG): A US-based biotechnology company is pleased to announce the successful filing of its provisional patent
Clearmind Medicine Submits Three Additional International Patent Applications for Innovative MDMA, Ibogaine and Ketamine Compounds
27 févr. 2024 07h58 HE
|
Clearmind Medicine Inc.
New patent applications build upon Clearmind’s broad IP protection in the psychedelic space Vancouver, Canada, Feb. 27, 2024 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq, CSE: CMND), (FSE:...
SciSparc-Clearmind Partnership Yields Three New International Patent Applications for MDMA, Ibogaine and Ketamine Compounds
27 févr. 2024 07h58 HE
|
SciSparc Ltd
TEL AVIV, Israel, Feb. 27, 2024 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC) ("Company" or "SciSparc"), a specialty clinical-stage pharmaceutical company focusing on the development of therapies...
PharmAla named an Intellectual Property Ontario Client
22 févr. 2024 08h55 HE
|
PharmAla Biotech
PharmAla recieves a non-dilutive grant from IP Ontario (IPON) to support its patent work in international markets.